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Gene expression proﬁlingBreast cancer is the second leading cause of death by cancer in women. To identify biomarkers with potential
diagnostic and therapeutic utilities in breast cancer, gene expression proﬁling from real patient tissues was
used to discover signiﬁcantly deregulated genes out of 50,739 genes of human transcriptome. Total RNAs were
extracted, and the gene expression proﬁles of 32 cancerous and normal tissues were established using
Agilent gene expression microarray technology. The results were analyzed with Agilent GeneSpring 12.6
software. Here we provide detailed experimental methods and analysis for the microarray data, which have
been deposited into Gene Expression Omnibus (GEO) under GSE57297.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Experimental design, materials and methods
Tissue samples
Tissue samples were acquired from the Clinical and Translational
Science Institute (CTSI) at University of Florida, covering three subtypes
Sample source
location
Clinical and Translational Science Institute (CTSI), University
of Florida, Gainesville, Florida, United States.hemistry, University of Florida,
This is an open access article under thof breast cancer (Luminal A, Luminal B, Triple negative) [1,2] as well as
matched or unmatched normal tissue samples. All the human tissue
samples were stored at−80 °C before use.
RNA preparation
Total RNA was isolated and puriﬁed from frozen tissue samples
using RNeasy Lipid Tissue Mini Kit and RNase-Free DNase Set (Qiagen,
Chatsworth, CA) according to manufacturer's protocols. The quality of
total RNA was strictly controlled by several parameters. The RNA
extracts were ﬁrst analyzed by Nanodrop 2000 (Thermo Fisher
Scientiﬁc, Waltham, MA) and gel electrophoresis. RNA quality was
determined by the A260/A280 ratio (close to 2), A260/A230 (close to
2), and the presence of two distinct ribosomal bands on gel electropho-
resis. QualiﬁedRNAswere further tested usingAgilent 2100Bioanalyzer
(Agilent Technologies, Santa Clara, CA), and samples with 28S/18S
RNA ratio N1 were selected for gene expression proﬁling [3]. Thirty-
two samples were ﬁnally tested, among which two samples C501
(Luminal A) and N513 (normal) were from the same patient, others
are unmatched samples.
RNA labeling and hybridization
Cyanine-3 (Cy3) labeled cRNAwas prepared from 100 ng RNA using
the One-Color Low Input Quick Amp labeling kit (Agilent, Valencia, CA)
according to manufacturer's instructions, followed by RNeasy Mini Kit
(Qiagen, Valencia, CA) puriﬁcation. Dye incorporation and cRNA yield
were checked with the NanoDrop Spectrophotometer (NanoDrop
Technologies, Inc.).e CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Volcano plots showing the distribution of the gene expression fold changes in each subgroup (A) Luminal A, (B) Luminal B, and (C) Triple negative comparedwith normal controls.
Geneswith absolute fold change≥2 and p-value≤ 0.05 are indicated in red. Plots are generated using GeneSpring 12.6withmoderated t-test and Benjamini–Hochberg testing correction.
Fig. 2. Heat map showing different expression pattern of 779 genes out of 50,739 biological probes after one-way ANOVA test with a corrected p-value b 0.05 and fold change ≥2 in all
three breast cancer subtypes using GeneSpring 12.6 software. The heat map indicates up-regulation (red), down-regulation (green), and mean gene expression (black). The columns
represent individual tissue samples covering three breast cancer subtypes: Luminal A (red), Luminal B (yellow), and Triple negative (purple) as well as normal samples (blue). The
rows represent individual genes.
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For hybridization, 0.6 μg of Cy3-labeled cRNA [4] (speciﬁc
activity N 8 pmol Cy3/μg cRNA) was fragmented at 60 °C for 30 min in
a reaction volume of 25 μL containing 1× Agilent fragmentation buffer
and 2× Agilent blocking agent following manufacturers' instructions.
On completion of the fragmentation reaction, 25 μL of 2× Agilent
hybridization buffer was added to the fragmentation mixture and
hybridized to Agilent Whole Human Genome Oligo Microarrays
(GPL17077) for 17 h at 65 °C in a rotating Agilent hybridization oven.
Microarray scanning
After hybridization, microarrays were washed for 1 min at room
temperature with GE Wash Buffer 1 (Agilent) and 1 min with 37 °C
GE Wash buffer 2 (Agilent), then dried using Agilent stabilization and
drying solution. Slides were scanned immediately after washing on
the Agilent DNA Microarray Scanner (G2505C) using one color scan
setting for 1 × 60k array slides (Scan Area 61 × 21mm, Scan resolution
3 μM, Dye channel is set to Green and Green PMT is set to 100%) [5].
Data normalization and quality control
The raw signals were log transformed and normalized using the
Percentile shift normalizationmethod, the valuewas set at 75th percen-
tile (Agilent GeneSpring 12.6 manual, 22.2.1, P584) [6]. For each probe,
the median of the log summarized values from all the samples was
calculated and subtracted from each of the samples to get transformed
baseline. The parameter values for experimental grouping were set as
Luminal A, Luminal B, Triple negative, and Normal.
Probes with normalized intensity values below 20th percentile were
ﬁltered out using the “Filter probe sets by Expression” option. This
resulted in 42,875 genes, which were further ﬁltered to exclude probes
with standard deviation b1 in all groups, resulting in 16,822 genes.
Differential expression
Volcano plots, representing the distribution of the fold changes and
p-values (obtained from moderated t-test [7]) of the above 16,822
genes, were shown in Fig. 1 corresponding to each subgroup (Luminal
A, Luminal B, and Triple negative). The moderated t-test is one of the
statistical tests provided by the GeneSpring 12.6 software as amodiﬁca-
tion of the unpaired t-test (Agilent GeneSpring 12.6 manual, 22.3.7,
P589).
Furthermore, 779 genes were identiﬁed with p-value ≤ 0.05 (One-
Way ANOVA with asymptotic computation and Benjamin–Hochbergmultiple testing corrections) and fold change≥2 [8,9] in all three breast
cancer subtypes. The heat map for these 779 genes is shown in Fig. 2.Conclusion
Herein we described the gene regulation information for breast
cancer gene proﬁling using Agilent SurePrint G3 Human Gene
Expression Microarray technology. Our gene expression microarray
data provided an important resource for exploring and identifying
gene biomarkers involved in breast cancer.Disclosures
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